The excretion study of 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide in rats

Introduction: The 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide (ODASA) is a newcarbonic anhydrase II inhibitor for open-angle glaucoma treatment, but the excretion study of this compound has not been performed yet. Aim: Calculation of excretion parameters of ODASAand its metabolites in urine and feces in rats. Materials and Methods: The ODASA excretion was investigated on 6 Wistar rats. The 1% suspension of ODASA was instilled into each eye in a volume of 20μL (1.6 mg/kg). Excreta were collected using metabolic cages. Sampling of feces was performed every 24 h for 384 h after the administration. Urine was taken frequently in first day of experiment: 4 h, 8 h and 12 h after administration. Samples was stabilized and frozen (temperature <-70°C). Quantification of ODASA, 4-[5-(hydroxymethyl)-1,3,4-oxadiazole-2-yl]-benzenesulfonamide (M1), N-hydroxy-4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide (M2), 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonic acid (M3) was carried out by HPLC-ESI-MS/MS. M2 was unstable in samples, and its content was calculated by summing the concentrations of M2 and its degradation product M3. Kinetex Phenyl Hexyl column (50*4.6 mm, 2.6 µm) was used for chromatographic separation. Results: The developed bioanalytical methods for rat excreta analysis were validated in the range of 10-10000 ppb for ODASA and M1, 1-1000 ppb – for M2, and 5-5000 ppb – for M3. Part of 16.29±1.60% of the active compound was eliminated in unchanged form, 80.27±1.68% – in the form of M1, and 3.43±0.33% – in form of M2 (М±SEM). The drug is mainly excreted by renal route: 14.22±1.43% in the form of ODASA, 69.90±1.80% – in the form of M1, and 1.88±0.24% – in the form of M2 (М±SEM). The highest rate of renal excretion of the studiedcompounds was observed in period of 8-12 hours after administration. The complete elimination of ODASA was achieved through 360 h after administration. Conclusion: Most part of ODASA is eliminated in the form of M1. The main route of excretion is renal. The use of validated bioanalytical methods guaranteed reliability of the obtained data.

Authors

Institutions

Publication Details

Journal
Research Results in Pharmacology
Published
2025-12-25
DOI
https://doi.org/10.18413/rrpharmacology.11.524
Primary Topic
Glaucoma and retinal disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The excretion study of 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide in rats

I. I. Yaichkov, N. N. Volkhin, Anton A. Shetnev, М. К. Корсаков et al.
Research Results in Pharmacology
Glaucoma and retinal disorders
article

The excretion study of 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide in rats

I. I. Yaichkov, N. N. Volkhin, Anton A. Shetnev, М. К. Корсаков, Alexander L. Khokhlov
article en

Abstract

Introduction: The 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide (ODASA) is a newcarbonic anhydrase II inhibitor for open-angle glaucoma treatment, but the excretion study of this compound has not been performed yet. Aim: Calculation of excretion parameters of ODASAand its metabolites in urine and feces in rats. Materials and Methods: The ODASA excretion was investigated on 6 Wistar rats. The 1% suspension of ODASA was instilled into each eye in a volume of 20μL (1.6 mg/kg). Excreta were collected using metabolic cages. Sampling of feces was performed every 24 h for 384 h after the administration. Urine was taken frequently in first day of experiment: 4 h, 8 h and 12 h after administration. Samples was stabilized and frozen (temperature <-70°C). Quantification of ODASA, 4-[5-(hydroxymethyl)-1,3,4-oxadiazole-2-yl]-benzenesulfonamide (M1), N-hydroxy-4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide (M2), 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonic acid (M3) was carried out by HPLC-ESI-MS/MS. M2 was unstable in samples, and its content was calculated by summing the concentrations of M2 and its degradation product M3. Kinetex Phenyl Hexyl column (50*4.6 mm, 2.6 µm) was used for chromatographic separation. Results: The developed bioanalytical methods for rat excreta analysis were validated in the range of 10-10000 ppb for ODASA and M1, 1-1000 ppb – for M2, and 5-5000 ppb – for M3. Part of 16.29±1.60% of the active compound was eliminated in unchanged form, 80.27±1.68% – in the form of M1, and 3.43±0.33% – in form of M2 (М±SEM). The drug is mainly excreted by renal route: 14.22±1.43% in the form of ODASA, 69.90±1.80% – in the form of M1, and 1.88±0.24% – in the form of M2 (М±SEM). The highest rate of renal excretion of the studiedcompounds was observed in period of 8-12 hours after administration. The complete elimination of ODASA was achieved through 360 h after administration. Conclusion: Most part of ODASA is eliminated in the form of M1. The main route of excretion is renal. The use of validated bioanalytical methods guaranteed reliability of the obtained data.

Research Results in PharmacologyVol. 11(4)
Yaroslavl State Medical Academy (RU), Yaroslavl State Pedagogical University (RU)
Openalex Percentile: Top 28%
Glaucoma and retinal disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.